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Abstract
Tinea corporis is a superficial fungal infection that involves a circular pruritic rash on different
parts of the body. Many individuals recognize this type of fungal infection as “ringworm.” Tinea
corporis thrives in areas of the body that experience humidity and friction and can be spread
from person to person. Vulnerable populations such as those in detention centers are more
susceptible due to the environment and close quarters. During 10 days of reflective practice,
more than half of the patients cared for developed reoccurring tinea corporis after treatment with
fluconazole. After conducting a literature review, a variety of medications were identified for the
treatment of tinea corporis, including fluconazole, terbinafine, and itraconazole. The medication
regimens analyzed, revealed that itraconazole was the best for reducing the reoccurrence of tinea
corporis. According to the literature, 100 mg of itraconazole should be given once daily for two
weeks, which was not reflective of local practice. As a quality improvement project, the use of
100 mg of itraconazole by mouth for two weeks was implemented, and follow-up was performed
at four weeks by assessing the elimination of tinea corporis according to the absence of itching,
erythema, hypopigmentation, and breakdown of the skin. Individual skin sites were documented
upon assessment of infection, and if consent was given, photographs were obtained and
compared. The modification of treatment was successful. After treatment, the patient sites
appeared clear with no circular pruritic rash. The project was found to reduce the cost of
medication required for retreatment as well as the reoccurrence of tinea corporis among patients
in the facility.
Keywords: tinea corporis, fungal infections, jail, skin, antifungal, medication, detainees,
prison, Dermatophytes
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Implementation of Itraconazole to Reduce Reoccurrence of Tinea Corporis in a
Correctional Facility
Tinea corporis is a fungal infection that can occur throughout the body. Also known as
ringworm, the diagnosis of tinea corporis is based on skin assessment, which includes evaluation
of the site, size, and symptoms, such as pruritis. Tinea corporis is treated with either topical or oral
medication regimens depending on the severity. If it reoccurs, current evidence-based practice
suggests using oral medications. Tinea corporis and tinea cruris are usually treated with a topical
antifungal agent unless the infection is unresponsive, involves an extensive area, is chronic, or is
difficult to access. In these cases, oral antifungals are frequently used (Sanmano et al., 2003).
A quality improvement project was conducted for the treatment of tinea corporis. Before
the project, fluconazole was used at 150 mg by mouth for three days. After 10 days of reflective
practice and review, tinea corporis was found to reoccur with this regimen, which was not
supported in the literature. In an effort to eliminate reoccurrence, the treatment was modified by
implementing a new prescription regimen that has supporting evidence for reducing reoccurrence
of tinea corporis infections.
A search of the literature revealed that the use of itraconazole at 100 mg by mouth once
a day for 14 days is recommended to prevent reoccurrence of tinea corporis. Itraconazole is an
orally active triazole-antifungal agent that has been demonstrated to be safe and effective in the
treatment of dermatophyte infections. Dermatophyte infections have been reported to respond
well to short courses of itraconazole because of the drug's high affinity for the skin.
Pharmacokinetic studies have demonstrated persistence of the drug in the stratum corneum for 2
to 4 weeks after discontinuation of treatment (Pariser et al., 1994).
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The goal of the quality improvement project was to convert evidence-based literature
into clinical practice by implementing a new prescription regimen that has supporting evidence
in reducing reoccurrence of tinea corporis infections. The resulting implementation would be
cost effective in the long term and reduce reoccurrence. It could also provide a cleaner
environment for patients living in close quarters.

Clinical Practice Problem
Reoccurrence of tinea corporis was identified as one of the main three predicaments
during 10 days of comprehensive reflective practice. After providing care for symptomatic
patients with tinea corporis, more than half of the patients required secondary treatment for
reoccurrence of tinea corporis after using 150 mg of fluconazole for three days by mouth. The
increased incidence of reoccurrence of tinea corporis raised concern due to returning visits for
secondary treatment for reoccurrence symptomatic tinea corporis and high use of medication,
medication cost, and prolonged treatment. Thus, a quality improvement project was performed
for this population.
The study population was comprised of incarcerated symptomatic patients between the
ages of 19 and 57 years with tinea corporis, and the intervention was the implementation of
itraconazole at 100 mg per os (P.O.) daily for 2 weeks. The intervention was compared with
fluconazole by mouth at 150 mg for 3 days or topical miconazole on the affected area for 7 days.
The studied outcome was the elimination of tinea corporis infections and their reoccurrence. The
study was carried out over 4 weeks.
Literature Review
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Various databases were searched, including PubMed, Cochrane, Indiana Journal of
Dermatology, EBSCO, MEDLINE, and UpToDate. A search of the literature was organized and
revealed a variety of medication regimens that minimize the reoccurrence of tinea corporis.
Medication regimens include fluconazole, terbinafine, and itraconazole. Specifically, the benefits
of itraconazole have been compared to other regimens, and it has been proven to be most
beneficial. Although side effects have been identified, these adverse effects are likely to be seen
in patients on long-term treatment with fluconazole for the treatment of other diseases. Providers
should be vigilant in monitoring for these adverse effects and consider dose adjustments or
therapeutic alternatives where appropriate (Davis et al., 2019).
Itraconazole is ideal for the treatment of cutaneous mycosis and has produced a
consistently high cure rate. Current treatment regimens, especially pulse therapy, produce fewer
side-effects and greater patient compliance (Sanmano et al., 2003). Itraconazole is superior to
fluconazole, griseofulvin, and terbinafine, and fluconazole is superior to griseofulvin. The results
were calculated in comparison to griseofulvin based on cure rates. Thus, itraconazole was the
most effective treatment out of the four treatments tested in the study, followed by fluconazole
(daily), terbinafine, and griseofulvin in the context of an altered dermatophytosis epidemic in
India (Singh et al., 2020).
Project Design
There are several quality improvement processes for organizations that cover a wide
range of activities. As organizations have unique structures, histories, and challenges that
influence the change process, they need to consider these intra- and inter-organizational factors
when making decisions regarding what kind of quality improvement process will work best
(Powell et al., 2008).
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In the workplace environment examined, quality improvement is aided by management
and a health services administrator. During the course of a month, the health services
administrator reviews quality measures, evaluates measures for continuous improvement, and
emphasizes leadership involvement in quality improvement projects. To obtain approval to
conduct the quality improvement project, supporting evidence was presented with a literature
review along with the findings of 10 days of reflective practice.
For the quality improvement project, the supervisor and nursing staff were provided with
an overview of the 10-day reflective practice problem, and the problem in practice was
identified. An overview was provided in regard to the quality improvement project, current
practice, and literature review with implementation of the itraconazole treatment regimen for
reoccurring tinea corporis. The health services administrator was hesitant in the beginning and
wanted more education and literature. Once provided, it was further reviewed, another quality
improvement proposal was presented, and it was approved.
After approval, a letter of support was obtained from the health service administrator and
the management of the facility. Once this was obtained, the project proposal could be completed
and presented to the institutional review board at the University of Texas at El Paso. Approval
was obtained, but it was determined that the project was not based on research. Approval from an
institutional review board or research ethics committee is intended to protect the rights of human
subjects. Assurance that ethical standards are met is essential for educational research and quality
improvement projects involving human subjects (Oermann et al., 2021). A notification email was
received from the University of Texas that the Institutional Review Board determined that the
project was not research, and a work letter permitting the quality improvement project to go forth
at the worksite was obtained.
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The worksite is a privately-owned for-profit facility. The clinical site has one physician
who works remotely and two nurse practitioners in house. Among the current practicing staff,
fluconazole is used by the nurse practitioner. The project was discussed in person with staff and
the nurse practitioner to communicate updates and progress. Literature reviews were provided,
and medication regimens were discussed with the other nurse practitioner. She was very
supportive and willing to participate. Once the project was completed, evidence was presented
based on patient outcomes from follow-up at four weeks by assessing for elimination of tinea
corporis, which was evidenced by an absence of itching, erythema, hypopigmentation, and
breakdown of the skin.
Support was obtained from all staff and one provider. The project was well received
because adoption of the proposed implementation would help a population that is vulnerable to
infections such as tinea corporis, as well as significantly reduce its incidence, and prevent
reoccurrence. Furthermore, it would reduce the cost of medication required for retreatment.
Transitional Framework
A transitional framework was implemented for the quality improvement project based
on Lewin’s change model. His theoretical framework model is straightforward for the process of
change. “Unfreezing change” allows flexibility that is necessary as a learner gains knowledge
and equips the team or individual for the upcoming changes as the problem is identified (Burnes,
2020). During the “moving” stage, change arises from research for the intended purpose, and the
forces for change are greater than the individuals that resist change (Burnes, 2020). The final
stage, the “freezing” process, reinforces the change by stabilizing the change that was
implemented to find equilibrium and decrease the risk of regression (Burnes, 2020).
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The first step in this process in the project application was education and improving
understanding among providers and staff of the apparent practice issue and evidence-based
practice. The second step was then alteration, innovation, and explanation of outcomes of change
while remaining open so as to reduce refutation on the new implementation. The framework was
carried out by disseminating evidence supporting the replacement of the medication regimen of
150 mg of fluconazole by mouth for three days with 100 mg of itraconazole by mouth for two
weeks, as well as training the providers on the regimen’s use, contraindications, and benefits.
The third and final step in this framework was “refreezing,” which is integrating and
stabilizing a new equilibrium into the system so that it becomes habit and resists further
change (Wojciechowski et al., 2016). During the project, the use of itraconazole was
implemented and had a favorable outcome. The collaborating physician and practitioner
participated in the implementation. However, the nurse practitioner colleague left the facility,
and a new provider was not open to adaptation of the implementation. As a result, “unfreezing”
was needed to help in the adaptation of the implementation of itraconazole. The medication
regimen continues to be used on suitable patient populations, and the importance of evidencebased practice to improve patient outcomes is continually being stress. Having great success
requires teamwork and joint effort from all participating staff to improve the quality of care.
Quality Improvement Model
The quality improvement model selected for this project was the Plan, Do, Study, and
Act (PDSA) model. The first step of the PDSA cycle is citing a plan or hypothesis for
improvement (Taylor et al., 2014). The second step involves executing or carrying out the plan.
The third step is analysis or data interpretation. In the last step, a decision is made to either make
changes, adopt the new practice, or abandon the hypothesis (Taylor et al., 2014).
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During the “Plan” phase, patients who met criteria for the project were targeted and
identified through assessment. The “Do” phase involved application of implementation of the
medication regimen. The “Study” phase included monitoring and analyzing the progress of the
patient, the process and change of site improvement, and symptoms. Finally, the “Act” phase
involved implementing the use of itraconazole, adapting to change, and repeating the cycle based
on patient outcomes.
The effectiveness of the medication regimen was measured by review after two weeks
and at a follow-up at four weeks by assessing for elimination of tinea corporis. The assessment
was based on the absence of itching, erythema, hypopigmentation, and breakdown of the skin.
Individual skin sites were documented upon assessment of infection, and if consent was given,
photographs were obtained and compared at four weeks. Data from the 10-day reflective practice
were compared to data obtained during the project time frame on the incidence of tinea corporis.
Patient records were reviewed, and the results of treatment and effectiveness of the medication
regimen were analyzed.
Population
The population was incarcerated, symptomatic, male or female patients aged 19-57 years
with tinea corporis who were previously treated with fluconazole at 150 mg by mouth for 3 days
or topical miconazole on affected area for 7 days. Given the environment of the practice, all of
the patients were incarcerated in either the general population or isolation depending on the
extent of the criminal charges.
Inclusion
Patients were included if they had previously been diagnosed with tinea corporis with
previous treatment of fluconazole at 150 mg for three days or miconazole topical twice daily on
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affected area for seven days. Patients also had to have recent lab results and liver enzymes within
normal limits, no history of heart disease, no decreased kidney function, and no current
pregnancy.
Exclusion
Patients were excluded if they did not fit the proper criteria for administration of
itraconazole (those with liver function test levels out of normal limits, AST >40 units per liter, or
ALT >56 units per liter). Patients were also excluded if they had a history of liver dysfunction,
decreased kidney function, history of heart disease, or pregnancy. The risk of developing
antifungal-associated hepatotoxicity is multifactorial and is influenced by pre-existing liver
disease, chemical properties of the drug, patient demographics, comorbidities, drug-drug
interactions, environmental, and genetic factors. Antifungal-related liver injury typically
manifests as elevations in serum aminotransferase levels (Frank et al., 2016).
Methods
Data from the 10-day reflective practice were compared to information obtained after
changing the treatment regimen. During the 10-day reflective practice, eight patients who had
previously been treated with fluconazole experienced reoccurrence of tinea corporis. Eight
patients were treated, and all had the previous treatment regimen, normal liver function tests, and
no contraindications for Itraconazole use. Inspection of the site and its location, size, and
symptoms of pruritis were documented. If consent was given, a photograph of the site was
obtained immediately and again at the two-week follow-up. All patients were given identical
instructions for local hygienic care and advised to clean with soap when bathing, avoid the use of
any other topical agents, and always keep the infected areas dry and clean.
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Patients returned to the clinic every week following treatment, and treatment efficacy
was evaluated 2 weeks after treatment initiation (Sanmano et al., 2003). The nursing staff was
informed about the specifics for correct assessment of site documentation and consent forms.
Self-reporting of pruritis was used for patient assessment. A study conducted by Sanmano et al.
(2003) included patients diagnosed with tinea corporis from January 1997 to December1999.
The evaluation process used in the present study was modeled after that used by Sanmano et al.,
who evaluated patients two weeks after treatment based on signs, symptoms, and scrapings. Due
to limited resources, scrapings were not obtained in the present study, but signs and symptoms
were evaluated in terms of severity of redness, erythema, and scaling.
Patients were instructed to visit the clinic, and at each visit, the clinical morphology of the
infected skin was assessed, and clinical photography and fungal examinations were performed.
Clinical assessment of lesions was evaluated according to signs (severity of redness, erythema,
and scaling) and symptoms (pruritus, burning, and stinging). With consideration of the patient
population, this method of documentation for re-evaluation was used. The nursing staff was able
to assist with documentation of the completion of patients’ two-week follow-up visits in the clinic.
However, two of the eight patients could not be assessed upon the two-week follow-up because
they were released from incarceration, and there was no way of following up with them as one was
sent to another state, while the other was sent to another county.
Medication Costs
In the United States, the average cost of a single 150-mg dose of fluconazole is
approximately $12.00 (Vensel, 2002). According to GoodRX (2022), the price of itraconazole is
$8.41 per dose. Itraconazole has shown higher mycological and clinical cure rates. Patients who
were prescribed terbinafine have indicated that there is growing resistance to the drug and
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increased chances of failure of treatment of dermatophyte infections, and failure of therapy also
adds to the financial burden on patients (Bhati et al., 2019). According to Martin (1999),
approximately 70% of fluconazole-resistant isolates (MIC ≥ 25 mg/L) remain susceptible to
itraconazole in vitro, although data are limited, and itraconazole can be effective in treating
patients who are non-responsive to fluconazole treatment.
In anticipation of the quality improvement project, the cost and availability of
itraconazole were discussed with the health service administrator. The cost of 14 pills of
itraconazole was $117 dollars. Another element to consider for the project was the cost
effectiveness. On average, patients had previously received three 150-mg doses of fluconazole
on three separate occasions, which totaled to $144 dollars per patient with reoccurrence. All 8
patients were treated with fluconazole for an average of four times prior to use of itraconazole,
which means the total cost of fluconazole was $144 for each patient. Thus, for all 8 patients, the
cost of fluconazole was $1152, and they were still having reoccurrence. With the use of
itraconazole, the cost for all 8 patients would be $942, which demonstrates the cost effectiveness
of itraconazole.
Challenges
The effectiveness of the continuation of the same treatment regimen for an extended
duration in the partially cured group was not assessed due to patients leaving of the detention
facility without a way of contacting them for follow-up.
Findings and Outcomes
The findings of the quality improvement project were similar to the anticipated
outcomes. No patient had signs of reoccurrence of tinea corporis, and all symptoms subsided at
two weeks without returning at the four-week follow-up assessment. By using itraconazole,
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overall patient outcomes were improved. However, 1 of the 2 practicing nurse practitioners did
not embrace this medication regimen in their practice. The patients showed a decrease in
reoccurrence of tinea corporis within the two-week window of the medication adherence. This
outcome should decrease the overall cost for the facility by reducing the repeated administration
of medication for reoccurrence and repeated visits.

Figure 1
(Left) Tinea corporis after fluconazole treatment with reoccurrence. (Right) Tinea corporis after
itraconazole treatment at 2-week follow-up.

Conclusion
In conclusion, the use of itraconazole is superior to fluconazole at 150 mg by mouth for
3 days. According to previous studies, itraconazole is superior to fluconazole, griseofulvin and
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terbinafine, and fluconazole was superior to griseofulvin (Singh et al., 2020). Furthermore,
itraconazole is more cost-effective than fluconazole. This may encourage other providers to
question the medication regimens used in their current practice for tinea corporis and modify
them to improve patient care for vulnerable populations.
Implications for Practice
Current evidence-based practice indicates that the use of 100 mg of itraconazole by
mouth daily for 14 days is superior to 150 mg of fluconazole by mouth for reducing the
reoccurrence of tinea corporis. However, challenges were faced in the implementation of the new
treatment regimen. For instance, the patients were either placed in a general prisoner population
or in isolation. The placement of the patient could impact medication adherence, cleanliness, and
limited sharing of items. For this specific quality improvement project, overall patient-care
outcomes were assessed among incarcerated individuals from both isolated and general
populations. Another consideration is having access to patients after release from facilities and
follow-up care thereafter. The data obtained during this project could have considerable
significance for practice indications. Overall, the project provided evidence that itraconazole is
effective for reducing recurrence of tinea corporis and is more cost-effective than fluconazole.
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